APOTEA Apotea AB (publ)
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears. In addition, the company offers leasing and hiring out personnel to related companies, as well as marketing contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.…
Industry Peers
Pharmaceutical RetailersKey Statistics
About Apotea (STO: APOTEA)
›
Apotea (STO: APOTEA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Pharmaceutical Retailers industry, part of the Healthcare sector, and reports about 713 employees.
The shares were at 101.50 SEK on 19 November 2026, up 16.7% over 52 weeks. Its 52-week range is 54.42 SEK to 107.20 SEK: the price is 5.3% below the high and 86.5% above the low.
At a market capitalisation of 10.56B SEK, it trades at 40.8 times trailing earnings and 27.5 times forward earnings. The median trailing P/E of its 4 largest Pharmaceutical Retailers peers is 21.9, a premium of 86% for APOTEA. It pays a dividend yielding 0.59% (it pays out 24% of its earnings), against a median of 3.94% among the dividend payers in that peer group.
Apotea reports return on equity of 27.1%, an operating margin of 4.3% and revenue up 12.5% year over year.
Its debt exceeds its cash by 152.70M SEK, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 105.50 SEK is 3.9% above the current price. The next earnings report is expected on 4 February 2027.